Alfen: Dead cat bounce? Ayvens: Overhang cure. Belgian telcos: Hey! discontinues €5 offer, OBEL price increases from June 2025. B&S Group: Pulls FY EBITDA guidance in light of tariffs. D'Ieteren: CMD, 1Q25 Preview. Kendrion: Wrestling through difficult macro conditions. NN Group, ASR: Vote on Dutch pension reforms postponed. TKH Group: Not that bad, good progress at Eemshaven. UCB: US Most Favoured Nation initiative back on the agenda. Vastned: Good results, integration ongoing...
A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.